The hospital discharge study aimed to understand what happens to the sickest of the sick and to look specifically at benign prostatic hyperplasia (BPH) and adverse events. This study spanned 1998-2007 representing a 20 percent data sample from the Nationwide Inpatient Sample representing all discharges with a primary or secondary diagnosis of BPH, representing 6.4million discharges of 121 million eligible discharges.
Parsons indicated the incidence of acute urinary retention among BPH patients increased 300 percent through 2007 and when extrapolated to 2008 data, increased 400 percent. In contrast, the incidence of urinary tract infections, urinary retention and bladder stones showed no significant change. He added, increased hospital discharges for primary BPH is associated with acute renal failure and stable discharges for other associated conditions. Severe adverse events persist in this era of medication and surgical therapy for the management of BPH.
Kevin McVary, MD, Northwestern University, moderator of the AUA press conference, commented on this BPH study: “Oral therapies for BPH are common first-line treatment that can be effective in many men; however, it is imperative that patients be treated promptly if the drugs are not working. In many cases, surgical treatment for BPH can help prevent urinary retention, which can ultimately lead to acute renal failure that can be life-threatening.”
Presented by J. Kellogg Parsons, MD, et al. at the American Urological Association (AUA) Annual Meeting - May 14 - 19, 2011 - Walter E. Washington Convention Center, Washington, DC USA
View slides from this presentation by J. Kellogg Parsons, MD, MHS
Reported by Karen Roberts, Medical Writer, UroToday.com
View Full AUA 2011 Meeting Coverage
